Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

Aditi Dhir, MD, discusses risk-based stratification in patients with epithelioid and synovial sarcoma.

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

Faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men. 

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Jonathan C. Trent, MD, PhD, discusses the role of circulating tumor DNA in soft tissue sarcoma. 

Gilberto de Lima Lopes, MD, discusses the appropriate duration of immunotherapy in lung cancer, treatment-related adverse events, and remaining challenges faced in the space.

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Jonathan C. Trent, MD, PhD, discusses research efforts in bone and soft tissue sarcomas.

Gina Z. D'Amato, MD, discusses the evolution of treatment in sarcoma, the use of next-generation sequencing, and predictive and prognostic biomarkers under investigation in the space.

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.

Gilberto De Lima Lopes, MD, discusses how he navigates challenges caused by COVID-19 to continue to provide optimal care to his patients with cancer.

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Gina Z. D'Amato, MD, discusses the emerging role of next-generation sequencing in sarcoma.

Richa Dawar, MD, discusses challenges with the use of neratinib in patients with metastatic HER2-positive breast cancer.

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.

Elisa Krill-Jackson, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in the treatment of patients with metastatic breast cancer.